Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial

Current Medical Research and Opinion

Volumn 21, Issue 8, 2005, Pages 1181-1190

  Fleischmann, Roy M ^a,h   Cohen, S B ^a   Moreland, L W ^b   Schiff, M ^c   Mease, P J ^d   Smith, D B ^e   Keenan, G ^f   Kremer, J M ^g  

^a RADIANT RESEARCH   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Denver Arthritis Clinic PC   (United States)

^d Seattle Rhumatology Associates   (United States)

^e Rheumatology Associates   (United States)

^f Departments of Biostatistics and Epidemiology and Outcomes Research   (United States)

^g CENTOCOR INC   (United States)

^h UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Clinical response; Infliximab; Maintenance dosage; Methotrexate; Tapering

Indexed keywords

CORTICOSTEROID; ETANERCEPT; FOLIC ACID; FOLINIC ACID; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ARTHROPATHY; BRADYCARDIA; CLINICAL PROTOCOL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; LUPUS ERYTHEMATOSUS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; THORAX PAIN; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PAIN MEASUREMENT;

EID: 23744497141     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X53261     Document Type: Conference Paper

References (23)

1. Lee DM. Rheumatoid arthritis. Lancet 2001;358:903-11
2. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Int Med 1999;131:768-74
3. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001;44:1984-92
4. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two-year follow up of a double blind placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-23
5. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50
6. Goldbach-Mansky R, Lipsky PE. New concepts in the treatment of rheumatoid arthritis. Annu Rev Med 2003;54:197-216
7. Cannella AC, O'Dell JR. Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis? Curr Opin Rheumatol 2003;15:185-92
8. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88
9. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10
10. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63
11. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9
12. Bookbinder SA, Espinoza LR, Fenske NA, et al. Methotrexate: its use in the rheumatic diseases. Clin Exp Rheumatol 1984;2:185-93
13. Kevat SG, Hill WR, McCarthy PJ, et al. Pancytopenia induced by low-dose methotrexate for rheumatoid arthritis. Aust NZJ Med 1988;18:697-700
14. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31
15. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Ann Intern Med 1987;107:358-66
16. Weinblatt ME, Kaplan G, Germain BF, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994;37:1492-8
17. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65
18. Arnett FC, Edworthy SM, Bloch DA, et al. American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
19. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
20. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability, and pain scales. J Rheumatol 1982;9:789-93
21. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81
22. Breedveld FC, Kavanaugh AF, Cohen SB, et al. Early treatment of rheumatoid arthritis (RA) with adalimumab (HUMIRA®) plus methotrexate vs. adalimumab alone or methotrexate alone: The PREMIER study. Arthritis Rheum 2004;50:4096
23. Zink A, Listing J, Kary S, et al. No Relevant Escalation in Dosage of Infliximab or other Biologic Agents over 12 Months of Treatment - Results from the German Biologic Registry. 2004;50:S374